A large-scale retrospective multicenter study by Cortellini et al., which analyzed 1010 advanced NSCLC patients with PD-L1 TPS ≥ 50% treated with first-line pembrolizumab monotherapy, demonstrated that irAEs were linked to improved median PFS and OS, which is also in line with our findings [27]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.